Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Herantis Pharma Oyj, a biotech company, engages in the development of disease-modifying CDNF-based therapies for Parkinson's disease (PD). Its lead product in pipeline includes HER-096, an advanced small and synthetic chemical peptidomimetic version of the active parent as the preclinical xCDNF candidate for the treatment of PD and other neurodegenerative diseases; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein that is in Phase I study in patients with PD. The company was incorporated in 2008 and is based in Espoo, Finland.
Company Valuation
Based on key historical and expected multiples, the stock is fairly valued relative to its peers.
Target Price
The average target price of HRTIS.HE is 2.4 and suggests 39% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell